Skip to content

H2020FP7HORIZON

CEMM - Forschungszentrum fuer Molekulare Medizin GmbH

Country
ATAustria
Defence projects
0
Projects, all programmes
45
As coordinator
33
EU contribution (CORDIS)
EUR 32,229,204
Active
2008 to 2026

Projects

45 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
INITIATEINnate-ImmunomeTabolIsm as Antiviral TargEtH20202019ParticipantEUR 264,207
ChemRASChemical probing of transcriptional RAS effectorsH20202019CoordinatorEUR 178,157
ReSOLUTEResearch empowerment on solute carriers (ReSOLUTE)H20202018CoordinatorEUR 6,732,261
CHROMABOLISMChromatin-localized central metabolism regulating gene expression and cell identityH20202018CoordinatorEUR 1,980,916
chemosChemical Hematology: breaking resistance of hematological malignancies through personalized drug trialsH20202016CoordinatorEUR 146,668
CMILCrosstalk of Metabolism and InflammationH20202016CoordinatorEUR 1,701,011
SLIMSynthetic Lethal Interactions with nucleophosMin 1H20202016CoordinatorEUR 178,157
GameofGatesSolute carrier proteins as the gates managing chemical access to cellsH20202016CoordinatorEUR 2,389,782
EpigenomeProgrammingAn experimental and bioinformatic toolbox for functional epigenomics and its application to epigenetically making and breaking a cancer cellH20202016CoordinatorEUR 1,281,205
LIBRALeading Innovative measures to reach gender Balance in Research ActivitiesH20202015ParticipantEUR 178,205
DrugsUPSolute carrier proteins and the uptake of cytotoxic approved drugsH20202015CoordinatorEUR 178,157
IMMUNOCOREInborn errors of innate immunity: systems genomics route to the core of the immune systemFP72013CoordinatorEUR 1,498,950
BERGBERG – Biomedical Epigenomics Research GroupFP72013CoordinatorEUR 100,000
INNATEDNASENSORA proteomic screen to identify cytoplasmic DNA sensor proteins mediating type I Interferon productionFP72013CoordinatorEUR 180,191
GENES, DRUGS AND BREAST CANCERDiscovering Gene-Drug Interactions in Breast Cancer With a Systematic and Genetically Tractable ModelFP72013ParticipantEUR 369,658
NONCANATMDNA damage response: ATMIN regulated non-canonical ATM activationFP72012CoordinatorEUR 100,000
AIRSHIPAcute Inflammation Resolution by Soluble Human Inhibitory ProteinFP72012CoordinatorEUR 150,000
BLUEPRINTA BLUEPRINT of Haematopoietic EpigenomesFP72011ParticipantEUR 654,265
HEM_IDHEMatopoietic cell IDentity : genetic and epigenetic regulation in normal and malignant hematopoiesisFP72011ParticipantEUR 255,444
EPICALSystematic Identification and Validation of Epigenetic Cancer Lesions by Chemical Biology and Functional GenomicsFP72011CoordinatorEUR 100,000

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.